MESO FY 2016 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

FY 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$43M+79.2% YoY

Gross Profit

$13M30.0% margin

Operating Income

-$56M-131.4% margin

Net Income

-$4M-9.7% margin

EPS (Diluted)

$-0.08

Cash Flow

Operating Cash Flow

-$88M

Free Cash Flow

-$89M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$684M

Total Liabilities

$156M

Stockholders' Equity

$528M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$43M	$24M	+79.2%
Gross Profit	$13M	-$35,000	+36628.6%
Operating Income	-$56M	-$113M	+50.7%
Net Income	-$4M	-$119M	+96.5%